Breakthrough in Duchenne Muscular Dystrophy Treatment: Capricor Therapeutics Unveils Promising 3-Year Efficacy Results for CAP-1002
Capricor Therapeutics, a biotech company dedicated to the development of transformative cell and exosome-based therapeutics for patients with rare disorders, has recently announced compelling three-year efficacy results from the HOPE-2 Open Label Extension Study of CAP-1002 in patients with Duchenne Muscular Dystrophy (DMD). These results reflect sustained and robust benefits in skeletal muscle function and potential cardiac stabilization, underscoring CAP-1002’s promise as an enduring treatment for this debilitating condition.
Groundbreaking Results in Skeletal Muscle Function
Conducted over a rigorous three-year period, the HOPE-2 Open Label Extension Study centered on the consistent assessment of performance of the upper limb (PUL 2.0), a critical measure of muscle function in patients with DMD. The findings were nothing short of remarkable. Patients receiving CAP-1002 treatment demonstrated a significant and sustained improvement in PUL 2.0 scores, with statistical significance marked at p
Comments